Réf :HematoStat.net ; 1 (11) : V29 Albiol N, Moreno C. Autoimmune Cytopenia in CLL: Prognosis and Management in the Era of Targeted Therapies. Cancer J. 2021 Jul-Aug 01;27(4):286-296. doi: […]

Réf :HematoStat.net ; 1 (11) : V28 Van Gelder M, Tournilhac O, Te Raa D, Visser HPJ. Front-line chemo- immunotherapy is not inferior to ibrutinib in CLL. Ann Oncol. 2021 […]

Réf :HematoStat.net ; 1 (11) : V27 Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Kantarjian HM, Keating MJ, Burger JA. Ibrutinib induces durable remissions in […]

There is no excerpt because this is a protected post.

Treating lymphoma is now a bit EZ-er Réf :HematoStat.net : 1 (11) : V26 DOI: 10.1182/bloodadvances.2020002773

CAR T-cell Therapy for Secondary CNS DLBCL Réf :HematoStat.net : 1 (11) : V25 DOI: 10.1182/bloodadvances.2021005292 

SARS-CoV-2-inducedremission of Hodgkin lymphoma Réf :HematoStat.net : 1 (11) : V24 DOI: 10.1111/bjh.17116 

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma Réf :HematoStat.net : 1 (11) : V23 DOI: 10.3324/haematol.2020.254045

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas Réf :HematoStat.net : 1 (11) : V22 DOI: 10.3324/haematol.2019.238675